Isoginkgetin

Isoginkgetin

SCHEMBL22459983

COc1ccc(-c2cc(=O)c3c(O)cc(O)c(-c4cc(-c5cc(=O)c6c(O)cc(O)cc6o5)ccc4OC)c3o2)cc1

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.80
MAPT P10636 3/20 0.80
KMT2A Q03164 3/20 0.80
USP2 O75604 2/20 0.80
TP53 P04637 2/20 0.80
KDM4E B2RXH2 1/20 0.80
HPGD P15428 1/20 0.80
ALOX15 P16050 1/20 0.80
HBB P68871 1/20 0.80
HSD17B10 Q99714 1/20 0.80
MMP3 P08254 2/20 0.72
MMP9 P14780 2/20 0.72
CYP1B1 Q16678 4/20 0.70
CYP1A1 P04798 3/20 0.70
CYP1A2 P05177 3/20 0.70
IP6K2 Q9UHH9 3/20 0.70
MAOB P27338 2/20 0.70
ALDH1A1 P00352 2/20 0.70
FLT3 P36888 2/20 0.70
NPC1 O15118 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isoginkgetin SCHEMBL30293900 1.00 MEN1 (0.80) MEN1MAPTKMT2AUSP2TP53
Sciadopitisin SCHEMBL1158050 0.96 MAPT (0.86) MEN1MAPTKMT2AUSP2TP53
Sciadopitisin SCHEMBL30996894 0.96 MAPT (0.86) MEN1MAPTKMT2AUSP2TP53
Kayaflavone SCHEMBL27350697 0.94 MEN1 (0.71) MEN1MAPTKMT2AUSP2TP53
Kayaflavone SCHEMBL30646162 0.94 MEN1 (0.71) MEN1MAPTKMT2AUSP2TP53
Bilobetin SCHEMBL13485655 0.94 MMP9 (0.80) MEN1MAPTKMT2AUSP2TP53
Bilobetin SCHEMBL31094029 0.94 MMP9 (0.80) MEN1MAPTKMT2AUSP2TP53
SCHEMBL17166015 0.93 MEN1 (0.74) MEN1MAPTKMT2AUSP2TP53
Ginkgetin SCHEMBL888410 0.92 MAPT (0.86) MEN1MAPTKMT2AUSP2TP53
Ginkgetin SCHEMBL31303838 0.92 MAPT (0.86) MEN1MAPTKMT2AUSP2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016777-A1 COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2024-01-18 US disclosed
US-20240016777-A1 COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2024-01-18 US disclosed
WO-2023250111-A1 COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) 2023-12-28 WO disclosed
US-11110105-B2 Compounds, composition and uses thereof for treating cancer INSTITUT GUSTAVE ROUSSY (FR) 2021-09-07 US disclosed
EP-3609878-B1 COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER ROUSSY INST GUSTAVE (FR) 2020-12-23 EP disclosed
US-20200297741-A1 COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER Institut National de la Santé et de la Recherche Médicale (FR) 2020-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200297741-A1 COMPOUNDS, COMPOSITION AND USES THEREOF FOR TREATING CANCER PTPRC, PTPRS, PTPRCAP MEN1 2190/4885MAPT 3210/4885KMT2A 3703/4885
US-11110105-B2 Compounds, composition and uses thereof for treating cancer PTPRC, PTPRS, PTPRCAP MEN1 2190/4885MAPT 3210/4885KMT2A 3703/4885
US-20240016777-A1 COMPOUNDS AND METHODS FOR TREATING VIRAL INFECTIONS THPO, SERPINB1, SERPINC1 MEN1 740/4885MAPT 2717/4885KMT2A 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.